期刊文献+

Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection

Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection
下载PDF
导出
摘要 Background: Postoperative early recurrence(ER) in patients with pancreatic ductal adenocarcinoma(PDAC) is frequently encountered after curative intent surgery. Nonetheless, clinical significance and risk factors of ER after surgery for PDAC have not been extensively investigated. The aim of this study was to determine preoperative risk predictors for ER in patients with PDAC after upfront surgery. Methods: Eighty-one consecutive patients with PDAC who underwent curative intent surgical resection at Kangbuk Samsung Hospital between January 2004 and May 2015 were enrolled. ER was defined as tumor relapse within 6 months after surgery. Results: ER occurred in 26 patients(32.1%), whereas 49 patients(60.5%) had late recurrence( ≥ 6 months after surgery), and 6 patients had no recurrence(7.4%). Univariate analysis showed that C-reactive protein(CRP) > 3.0 mg/dL, modified Glasgow prognostic score(mGPS) = 2, decrease of total lymphocyte count by > 50% of baseline value in the preoperative period, prognostic nutritional index(PNI) < 45, neutrophilto-lymphocyte ratio(NLR) ≥ 3, and preoperative maximum standardized uptake value(SUVmax) were significantly associated with ER. Multivariate logistic regression analysis revealed that CRP > 3.0 mg/dL, decrease of total lymphocyte count by > 50% of baseline value, and preoperative SUVmax were significant and independent contributors of ER in patients with resectable PDAC who underwent curative intent surgery. Conclusions: Postoperative ER for resectable PDAC was frequent with poor prognosis after curative intent upfront surgery. It is reasonable to suggest that there is a subgroup of resectable PDAC patients at highrisk of ER and neoadjuvant therapy should be considered in these patients in a clinical trial setting. Background: Postoperative early recurrence(ER) in patients with pancreatic ductal adenocarcinoma(PDAC) is frequently encountered after curative intent surgery. Nonetheless, clinical significance and risk factors of ER after surgery for PDAC have not been extensively investigated. The aim of this study was to determine preoperative risk predictors for ER in patients with PDAC after upfront surgery. Methods: Eighty-one consecutive patients with PDAC who underwent curative intent surgical resection at Kangbuk Samsung Hospital between January 2004 and May 2015 were enrolled. ER was defined as tumor relapse within 6 months after surgery. Results: ER occurred in 26 patients(32.1%), whereas 49 patients(60.5%) had late recurrence( ≥ 6 months after surgery), and 6 patients had no recurrence(7.4%). Univariate analysis showed that C-reactive protein(CRP) > 3.0 mg/dL, modified Glasgow prognostic score(mGPS) = 2, decrease of total lymphocyte count by > 50% of baseline value in the preoperative period, prognostic nutritional index(PNI) < 45, neutrophilto-lymphocyte ratio(NLR) ≥ 3, and preoperative maximum standardized uptake value(SUVmax) were significantly associated with ER. Multivariate logistic regression analysis revealed that CRP > 3.0 mg/dL, decrease of total lymphocyte count by > 50% of baseline value, and preoperative SUVmax were significant and independent contributors of ER in patients with resectable PDAC who underwent curative intent surgery. Conclusions: Postoperative ER for resectable PDAC was frequent with poor prognosis after curative intent upfront surgery. It is reasonable to suggest that there is a subgroup of resectable PDAC patients at highrisk of ER and neoadjuvant therapy should be considered in these patients in a clinical trial setting.
出处 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS CSCD 2018年第5期450-455,共6页 国际肝胆胰疾病杂志(英文版)
关键词 Early recurrence Pancreatic ductal adenocarcinoma Preoperative risk factors C-reactive protein Maximum standardized uptake value Early recurrence Pancreatic ductal adenocarcinoma Preoperative risk factors C-reactive protein Maximum standardized uptake value
  • 相关文献

参考文献1

二级参考文献29

  • 1Nitecki SS;Sarr MG;Colby TY.Long-term survival after resection for ductal adenocarcinoma of the pancreas,1995(01).
  • 2Hans G. Beger,Frank Gansauge,Markus W. Büchler,Karl Heinz Link.Intraarterial Adjuvant Chemotherapy after Pancreaticoduodenectomy for Pancreatic Cancer: Significant Reduction in Occurrence of Liver Metastasis[J]. World Journal of Surgery . 1999 (9)
  • 3Katsumi Amikura,Masao Kobari,Seiki Matsuno.The time of occurrence of liver metastasis in carcinoma of the pancreas[J]. International Journal of Pancreatology . 1995 (2)
  • 4JemalA,Siegel R,Ward E,Murray T,Xu J,Smigal C,Thun MJ.Cancer statistics. CA A Cancer Journal for Clinicians . 2006
  • 5Ministry of Health and Welfare.2002 annual report of the Korea Central Cancer Registry. . 2003
  • 6Westerdahl J,Andren-Sandberg A,Ihse I.Recurrence of exocrine pancreatic cancer-local or hepatic. Hepato Gastroenterology . 1993
  • 7MB Menke-Pluymers,JH Klinkenbijl,M Tjioe,J Jeekel.Treatment of locoregional recurrence after intentional curative resection of pancreatic cancer. Hepato Gastroenterology . 1992
  • 8Tobita K,Kijima H,Dowaki S,Kashiwagi H,Ohtani Y,Oida Y,Yamazaki H,Nakamura M,Ueyama Y,Tanaka M,Inokuchi S,Makuuchi H.Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. International Journal of Molecular Medicine . 2003
  • 9Watanabe I,Hasebe T,Sasaki S,Konishi M,Inoue K,Nak- agohri T,Oda T,Mukai K,Kinoshita T.Advanced pancre- atic ductal cancer: f ibrotic focus and beta-catenin expression correlate with outcome. Pancreas . 2003
  • 10Oettle H,Post S,Neuhaus P,Gellert K,Langrehr J,Ridwelski K,Schramm H,Fahlke J,Zuelke C,Burkart C,Gutberlet K,Kettner E,Schmalenberg H,Weigang-Koehler K,Bechstein WO,Niedergethmann M,Schmidt-Wolf I,Roll L,Doerken B,Riess H.Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. The Journal of The American Medical Association . 2007

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部